1. Nezhat C, King LP, Paka C, Odegaard J, Beygui R (2012) Bilateral thoracic endometriosis affecting the lung and diaphragm. JSLS. 16: 140-2.
2. Fuldeore MJ, Soliman AM (2017) Prevalence and Symptomatic Burden of Diagnosed Endometriosis in the United States: National Estimates from a Cross-Sectional Survey of 59,411 Women. Gynecol Obstet Invest 82:453-61.
3. Kvaskoff M, AW, Horne SA (2017) Missmer. Informing women with endometriosis about ovarian cancer risk. Lancet, 390: 2433-4.
4. Vered H. Eisenberg, Clara Weil, Gabriel Chodick, Varda Shalev (2017) Epidemiology of endometriosis: a large population-based database study in a 2-million-member health care provider. BJOG. 2017 Apr 26 Published online 2017 Apr 26.
5. Morassutto, C, Monasta L, Ricci G, Barbone F, Ronfani L (2016). Incidence and Estimated Prevalence of Endometriosis and Adenomyosis in Northeast Italy: A Data Linkage Study. PloS one 11: e0154227.
6. Greene R, Stratton P, Cleary SD, Ballweg ML, Sinaii N (2009) Diagnostic experience among 4,334 women reporting surgically diagnosed endometriosis. Fertil Steril 91: 32–9.
7. Sampson JA (1925) Endometrial carcinoma of the ovary, arising in endometrial tissue in that organ. Arch. Surg. 10: 1–72.
8. JA Sampson (1925) Heterotopic or misplaced endometrial tissue,” American Journal of Obstetrics and Gynecology 10: 649–64.
9. J Halme, MG Hammond, JF Hulka (1984) Retrograde menstruation in healthy women and in patients with endometriosis. Obstetrics and Gynecology, 64: 151-4.
10. Liu DTY, Hitchcock A (1986) Endometriosis: its association with retrograde menstruation, dysmenorrhoea and tubal pathology. Br J Obstet Gynaecol 93: 862.
11. Koyama N, Matsuura K, Okamura H (1993) Cytokines in the peritoneal uid of patients with endometriosis. Int J Gynaecol Obstet 43: 45-50.
12. Anderson DJ and Hill JA (1987) Interleukin-1 and endometriosis. Fertil Steril 48,894-5.
13. Cheong YC, Shelton JB, Laird SM, Richmond M, Kudesia G, Li TC (2002) IL-1, IL-6 and TNF-g concentrations in the peritoneal ¯uid of women with pelvic adhesions. Hum Reprod 17: 69-75.
14. Sikora J, Mielczarek-Palacz A, Kondera-Anasz Z (2012) Imbalance in cytokines from interleukin-1 family—role in pathogenesis of endometriosis. Am J Reprod Immunol. 68: 138–45.
15. Wu MH, Wang CA, Lin CC, Chen LC, Chang WC, Tsai SJ (2005) Distinct regulation of cyclooxygenase-2 by interleukin-1beta in normal and endometriotic stromal cells. J Clin Endocrinol Metab 90: 286–95.
16. Santulli P, Borghese B, Chouzenoux S, Streuli I, Borderie D, de Ziegler D (2013) Interleukin-19 and interleukin-22 serum levels are decreased in patients with ovarian endometrioma. Fertil Steril 99: 219-26.
17. Bhyan SB, Zhao L, Wee Y, Liu Y, Zhao M (2019) Genetic links between endometriosis and cancers in women. Peer J. 7: e8135.
18. Yotova IY, Quan P, Leditznig N, Beer U, Wenzl R, (2011) Abnormal activation of Ras/Raf/MAPK and RhoA/ROCKII signalling pathways in eutopic endometrial stromal cells of patients with endometriosis. Hum Reprod 26: 885–97.
19. Lydon JP (1995) Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev. 1995;9: 2266–78.
20. Nabizadeh JA, Manthey HD, Steyn FJ, Chen W, Widiapradja A (2016) The complement C3a receptor contributes to melanoma tumorigenesis by inhibiting neutrophil and CD4+ T cell responses. The Journal of Immunology 196: 4783–92 .
21. Yamada Y, Takayama KI, Fujimura T, Ashikari D, Obinata D (2017) A novel prognostic factor TRIM44 promotes cell proliferation and migration, and inhibits apoptosis in testicular germ cell tumor. Cancer Science 108: 32-41.
22. Zhang Y, Bao W, Wang K, Lu W, Wang H, Tong H, Wan X. SOX17 is a tumor suppressor in endometrial cancer. Oncotarget. 2016;7: 76036–46.
23. Balgkouranidou I, Chimonidou M, Milaki G, Tsaroucha E, Kakolyris S (2016) SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer. Clin Chem Lab Med 54: 1385-93.
24. Fu DY, Tan HS, Wei JL, Zhu CR, Jiang JX (2015) Decreased expression of SOX17 is associated with tumor progression and poor prognosis in breast cancer. Tumour Biol 36: 8025–34.
25. Kuo IY, Wu CC, Chang JM, Huang YL, Lin CH (2014) Low SOX17 expression is a prognostic factor and drives transcriptional dysregulation and esophageal cancer progression. Int J Cancer 135: 563-73.
26. Zhang W, Glockner SC, Guo M, Machida EO, Wang DH (2008) Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res 68: 2764-72.
27. Walker CJ, O’Hern MJ, Serna VA, Kurita T, Miranda MA, et al. (2017) Novel SOX17 frameshift mutations in endometrial cancer are functionally distinct from recurrent missense mutations. Oncotarget 8: 68758–68.
28. Treloar SA, Wicks J, Nyholt DR, Montgomery GW, Bahlo M, et al. (2005) Genomewide linkage study in 1,176 affected sister pair families identifies a significant susceptibility locus for endometriosis on chromosome 10q26, Am J Hum Genet 77: 365-76.
29. Govatati S, Kodati VL, Deenadayal M, Chakravarty B, Shivaji S, Bhanoori M., Yin X., Pavone M.E., Lu Z., Wei J., et al. (2014) Mutations in the pten tumor gene and risk of endometriosis: A case-control study increased activation of the pi3k/akt pathway compromises decidualization of stromal cells from endometriosis. Hum. Reprod 29: 324–36.
30. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, et al. (2005) Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11: 63-70.
31. Lv J, Zhu Q, Jia X, Yu N, Li Q (2016) In Vitro and In Vivo Effects of Tumor Suppressor Gene PTEN on Endometriosis: An Experimental Study. Med Sci Monit 22: 3727–36.
32. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K et al. (2010). ARID1A mutations in endometriosis-associated ovarian carcinomas. The New England journal of medicine, 363: 1532–43.
33. Anglesio MS, Bashashati A, Wang YK (2015) Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden. J Pathol 236: 201–9.
34. Chene G, Ouellet V, Rahimi K, Barres V, Provencher D, et al. (2015) The ARID1A pathway in ovarian clear cell and endometrioid carcinoma, contiguous endometriosis, and benign endometriosis. International Journal of Gynecology & Obstetrics 130: 27-30.
35. Guan B, Rahmanto YS, Wu RC (2014) Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis. J Natl Cancer Inst 106: 146.
36. Borrelli GM, Abrao MS, Taube ET (2016) (Partial) Loss of BAF250a (ARID1A) in rectovaginal deep-infiltrating endometriosis, endometriomas and involved pelvic sentinel lymph nodes. Mol Hum Reprod 22: 329-37.
37. Ashrafi M, Sadatmahalleh SJ, Akhoond MR, Talebi M (2016) Evaluation of risk factors associated with endometriosis in infertile women. Int J Fertil Steril 10: 11–21.
38. Apostolopoulos NV, Alexandraki KI, Gorry A, Coker A (2016) Association between chronic pelvic pain symptoms and the presence of endometriosis. Arch Gynecol Obstet 2016; 293: 439-45.
39. Schliep KC, Mumford SL, Peterson CM (2015) Pain typology and incident endometriosis. Hum Reprod 30: 2427–38.
40. American College of Obstetricians and Gynecologists. Practice bulletin no. 114: management of endometriosis. Obstet Gynecol. 116: 223-36.
41. Kennedy S, Bergqvist A, Chapron C (2005) ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 20: 2698-704.
42. Taylor HS, Adamson GD, Diamond MP (2018) An evidence-based approach to assessing surgical versus clinical diagnosis of symptomatic endometriosis. Int J Gynaecol Obstet. 142: 131-42.
43. Fernando S, Soh PQ, Cooper M (2013) Reliability of visual diagnosis of endometriosis. J Minim Invasive Gynecol 20: 783-9.
44. Amaral VF, Ferriani RA, Sá MF (2006) Positive correlation between serum and peritoneal fluid CA-125 levels in women with pelvic endometriosis. Sao Paulo Med J 124: 223-7.
45. Khodaverdi S, Amini-Moghaddam S, Almassi Nokiani F, Hashemi N, Mohammad Beigi R (2018) Adnexal mass with extremely high levels of CA-125 and CA19-9 but normal Human Epididymis Protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA): Endometriosis or ovarian malignancy? A case report. Int J Reprod Biomed (Yazd)16: 413-6.
46. Jacobs Screening for ovarian cancer by CA-125 measurement. Lancet. 16: 889
47. Ian Jacobs, Robert C. Bast, The CA 125 tumour-associated antigen: a review of the literature, Human Reproduction, Volume 4, Issue 1, January 1989, Pages 1–12,
48. Park CM, Kim SY.Rupture of an endometrioma with extremely high serum CA-125 level (>10,000 IU/ml) and ascites resembling ovarian cancer. Eur J Gynaecol Oncol 2014; 35: 469-72.
49. Amaral VF, Ferriani RA, Sá MF (2016) Positive correlation between serum and peritoneal fluid CA-125 levels in women with pelvic endometriosis. Sao Paulo Med J 124: 223- 7.
50. Karli P (2019) The relationship of pelvic pain symptoms with CA-125 levels in endometriosis cases. Annals of Medical Research. 26: 1326-9.
51. Hirsch, Martin (2017) Diagnostic accuracy of Cancer Antigen 125 (CA125) for endometriosis in symptomatic women: A multi-center study. Euro Obstetrics Gynecology and Reproductive Biology, Volume 210: 102-7.
52. Kurata H, Sasaki M, Kase H, Yamamoto Y, Aoki Y, Tanaka K. Elevated serum CA-125 and CA19-9 due to the spontaneous rupture of ovarian endometrioma. Eur J Obstet Gynecol Reprod Biol 2002; 105: 75-76.
53. Agha Hosseini M, Aleyasin A, khodaverdi S, mahdavi A, Najmi Z (2009) Extra ordinary high CA-125 and CA19-9 serum levels in an ovarian endometrioma: Case report. J Fam Reprod Health 3: 67-70.
54. Agha Hosseini M, Aleyasin A, khodaverdi S, mahdavi A, Najmi Z (2009) Extra ordinary high CA-125 and CA19-9 serum levels in an ovarian endometrioma: Case report. J Fam Reprod Health 3: 67-70.
55. Zeimet AG, Marth C, Offner FA, Obrist P, Uhl-Steidl M, Feichtinger H, et al. (1996) Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. Gynecol Oncol. 62: 384-9.
56. Anastasi E, Granato T, Falzarano R, Storelli P, Ticino A, Frati L, et al. (2013) The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer. J Ovarian Res 6: 44.
57. Koninckx, PRMartin D (1994) Treatment of deeply infiltrating endometriosis. Curr Opin Obstet Gynecol 6: 231-41.
58. Koninckx, P.R., Meuleman, C., Demeyere, S., Lesaffre, E. and Cornillie, F.J. (1991) Suggestive evidence that pelvic endometriosis is a progressive disease, whereas deeply infiltrating endometriosis is associated with pelvic pain. Fertil. Steril., 55, 759–65.
59. Charles Chapron, Arnaud Fauconnier, Jean‐Bernard Dubuisson, Habib Barakat, Marco Vieira, Gérard Bréart, Deep infiltrating endometriosis: relation between severity of dysmenorrhoea and extent of disease, Human Reproduction, Volume 18, Issue 4, April 2003, Pages 760–6.
60. Kamergorodsky, G, Ayroza Ribeiro, PA, Longo Galvao, MA (2009) Histologic classification of specimens from women affected by superficial endometriosis, deeply infiltrating endometriosis, and ovarian endometriomas. Fertil Steri 92: 2074-7.
61. Anglesio MS, Papadopoulos N, Ayhan A (2017 ) Cancer-Associated Mutations in Endometriosis without Cancer. N Engl J Med 376: 1835–48.
62. Dawson A, Fernandez ML, Anglesio M, Yong PJ, Carey MS (2018) Endometriosis and endometriosis-associated cancers: new insights into the molecular mechanisms of ovarian cancer development. Ecancermedicalscience 12: 803.
63. LaGrenade A, Silverberg SG. Ovarian tumors associated with atypical endometriosis. Hum Pathol. 1988;19:1080–1084.
64. Wei JJ, William J, Bulun S. Endometriosis and ovarian cancer: a review of clinical, pathologic, and molecular aspects. Int J Gynecol Pathol. 2011;30(6):553–568. doi:10.1097/PGP.0b013e31821f4b85
65. Fukunaga M, Nomura K, Ishikawa E, Ushigome S. (1997) Ovarian atypical endometriosis; its close association with malignant epithelial tumours. Histopathology 30: 248-55.
66. Stern RC, Dash R, Bentley RC (2001) Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types. Int J Gynecol Pathol 20: 133–9.
67. Prefumo F, Todeschini F, Fulcheri E (2002) Epithelial abnormalities in cystic ovarian endometriosis. Gynecol Oncol. 84: 280–4.
68. Anglesio MS, Carey MS, Köbel M (2011) Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, Gynecol Oncol 121: 407-15.
69. Zhao C, Wu LS-F, Barner R. (2011) Pathogenesis of ovarian clear cell adenofibroma, atypical proliferative (borderline) tumor, and carcinoma: clinicopathologic features of tumors with endometriosis or adenofibromatous components support two related pathways of tumor development. J Cancer 2:94.
70. Groen RS, Gershenson DM, Fader AN. (2015) Updates and emerging therapies for rare epithelial ovarian cancers: one size no longer fits all. Gynecol Oncol 136: 373–83.
71. Tang H, Liu Y, Wang X et al (2018) Clear cell carcinoma of the ovary: clinicopathologic features and outcomes in a Chinese cohort. Medicine (Baltimore) 97: e10881
72. Fehniger J, Schiff PB, Pothuri B (2018) Successful treatment of platinum refractory ovarian clear cell carcinoma with secondary cytoreductive surgery and implantable transponder placement to facilitate targeted volumetric arc radiation therapy. Gynecol Oncol Rep 27: 11-14.
73. CW Tyler Jr, NC Lee, SJ Robboy (1991) The diagnosis of ovarian cancer by pathologists: how often do diagnoses by contributing pathologists agree with a panel of gynecologic pathologists? Am J Obstet Gynecol 164: 65-70.
74. JM Heaps, RK Nieberg, JS Berek (1990) Malignant neoplasms arising in endometriosis. Obstet Gynecol, 75: 1023-8.
75. Lim MC, Chun KC, Shin SJ,, Lee IH,, Lim KT, et al (2010) Clinical presentation of endometrioid epithelial ovarian cancer with concurrent endometriosis: A multicenter retrospective study Cancer Epidemiology Biomarkers and Prevention, 19: 398-4.
76. Terada T (2012) Endometrioid adenocarcinoma of the ovary arising in atypical endometriosis. Int J Clin Exp Pathol 5: 924–7.
77. Ogawa S, Kaku T, Amada S, Kobayashi H, Hirakawa T (2000) Ovarian endometoriosis associated with ovarian carcinoma: a clinicopathologic and immunohistochemical study. Gynecol Oncol 77: 298–304.
78. Okuda T, Sekizawa A, Purwosunu Y (2010) Genetics of endometrial cancers. Obstet Gynecol Int 2010: 984013.
79. Dutta S, Wang FQ, Phalen A, Fishman DA (2010) Biomarkers for ovarian cancer detection and therapy. Cancer Biol Ther 9: 668–77.
80. McCluggage (2020) Endometriosis‐related pathology: a discussion of selected uncommon benign, premalignant and malignant lesions. Histopathology 76: 76-92.
81. Prat J (2012) New insight into ovarian cancer pathology. Ann Oncol 23: 111–7.
82. Cont NT, Ferrero A, Peccatori FA (2015) Medical treatment of early stage and rare histological variants of epithelial ovarian cancer. Ecancermedicalscience 9: 584.
83. Eichhorn JH, Young RH, Clement PB, Scully RE (2002) Mesodermal (müllerian) adenosarcoma of the ovary: a clinicopathologic analysis of 40 cases and a review of the literature. Am J Surg Pathol 26: 1243 –58.
84. Pontrelli G, Cozzolino M, Stepniewska A, Bruni F, Pesci A (2016) Ceccaroni MJ. Primary vaginal Adenosarcoma with Sarcomatous overgrowth arising in recurrent endometriosis: feasibility of laparoscopic treatment and review of the literature. J Minim Invasive Gynecol.